HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dong-Lin Yang Selected Research

Estrogen Receptors

10/2022Discovery of fused benzimidazole-imidazole autophagic flux inhibitors for treatment of triple-negative breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Dong-Lin Yang Research Topics

Disease

7Neoplasms (Cancer)
10/2022 - 01/2016
3Glioblastoma (Glioblastoma Multiforme)
01/2021 - 01/2018
3Aplastic Anemia (Anemia, Hypoplastic)
04/2018 - 11/2009
3Graft vs Host Disease (Graft-Versus-Host Disease)
04/2018 - 02/2006
2Breast Neoplasms (Breast Cancer)
10/2022 - 01/2020
2Infections
07/2010 - 04/2008
2Hepatitis B
07/2010 - 04/2008
2Pathologic Complete Response
02/2010 - 06/2004
1Hepatocellular Carcinoma (Hepatoma)
02/2023
1Triple Negative Breast Neoplasms
10/2022
1Prostatic Neoplasms (Prostate Cancer)
09/2021
1Adenocarcinoma of Lung
06/2021
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
06/2021
1Epstein-Barr Virus Infections
04/2018
1Colorectal Neoplasms (Colorectal Cancer)
01/2018
1BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
02/2011
1Invasive Fungal Infections
12/2010
1Hematologic Diseases (Blood Diseases)
12/2010
1Neutropenia
12/2010
1Hepatitis
07/2010
1Bronchiolitis Obliterans Syndrome
07/2010
1Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
02/2010
1Myelodysplastic Syndromes (Myelodysplastic Syndrome)
11/2009
1Hereditary Spherocytosis
06/2009
1Hyperplasia
06/2009
1Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
12/2008
1Hepatic Veno-Occlusive Disease (Disease, Hepatic Veno-Occlusive)
12/2007
1Hematologic Neoplasms (Hematological Malignancy)
06/2004

Drug/Important Bio-Agent (IBA)

3benzimidazoleIBA
10/2022 - 01/2018
2Cyclosporine (Ciclosporin)FDA LinkGeneric
11/2009 - 04/2008
1indoleIBA
02/2023
1Estrogen ReceptorsIBA
10/2022
1Progesterone Receptors (Progesterone Receptor)IBA
10/2022
1imidazoleIBA
10/2022
1TriterpenesIBA
09/2021
1demethylzeylasteralIBA
09/2021
1Gefitinib (Iressa)FDA Link
06/2021
1Tyrosine Kinase InhibitorsIBA
06/2021
1RNA (Ribonucleic Acid)IBA
06/2021
1LactonesIBA
01/2021
1parthenolideIBA
01/2021
1SesquiterpenesIBA
01/2021
1CateninsIBA
01/2020
1Cyclin DIBA
01/2020
1imidazopyridineIBA
01/2020
1CytokinesIBA
04/2018
1Interleukin-6 (Interleukin 6)IBA
04/2018
1Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
01/2018
1Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA
01/2018
1Dihydrotachysterol (AT 10)IBA
01/2016
1Adrenal Cortex Hormones (Corticosteroids)IBA
12/2010
1Hepatitis B Surface Antigens (HBsAg)FDA Link
07/2010
1thymoglobulinFDA Link
11/2009
1ChromatinIBA
06/2009
1Granulocyte Colony-Stimulating Factor (G-CSF)IBA
02/2006

Therapy/Procedure

8Therapeutics
10/2022 - 11/2009
7Hematopoietic Stem Cell Transplantation
04/2018 - 12/2007
2Drug Therapy (Chemotherapy)
01/2020 - 06/2004
2Transplantation
04/2018 - 07/2010
1Aftercare (After-Treatment)
01/2021
1Stem Cell Transplantation
02/2010
1Retreatment
11/2009
1Splenectomy
06/2009
1Hemibody Irradiation
06/2004